The BetaShares DRUG ETF provides investors with exposure to leading global healthcare companies, hedged into Australian dollars.
ETF share prices are updated using end of day data from the ASX. FUM, fee and spread data is updated monthly, with a delay of up to 6 weeks. Refer to the ETF's PDS and the ASX website for up-to-date information.
This ETF invests in well-known global healthcare companies like Johnson & Johnson, Novartis and Glaxosmithkline. This ETF could be a solution for investors looking for targeted exposure to the global healthcare sector.
DRUG could be used by investors looking for a tactical exposure to global healthcare companies, while reducing currency risk through hedging strategies.
Dividend Yield
Dividend yield information is coming soon (how good is that!).
Got any other requests for our team?
We’re incorporating new data based on user feedback received in January 2021 — but we’re not done yet. Far from it.
Use the Contact page to send us your advice to make Best ETFs Australia even better.
You could earn up to $50 in Rask Australia credit, to use on Rask’s premium share research. To be eligible, send us your feedback, help us fix our site or make it better for everyone.
Distributions
DRP Status
The following warnings are applied by our ETF research team. Please know that these warnings are based on quantitative metrics and our internal methodology. These risks are not exhaustive and therefore they should not be relied upon. Always read the PDS of the function and speak to your financial adviser before acting on this information.
The BetaShares DRUG ETF provides investors with exposure to leading global healthcare companies, hedged into Australian dollars.
Two of the most popular ASX ETFs are the BetaShares Australia 200 ETF (ASX: A200) and the Vanguard Diversified High Growth Index ETF (ASX: VDHG).
Is the Vanguard Australian Shares Index ETF (ASX: VAS) a good option for long-term investors looking for healthy returns?
This brilliant (and free!) report is issued by Best ETFs Australia, a division of The Rask Group Pty Ltd. It is not a recommendation.
Speak to a financial professional before relying on this information and please read our Financial Services Guide (FSG).
General Financial Advice warning
The information on this website is general financial advice only. That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please read our Terms & Conditions and Financial Services Guide before using this website.
© Rask Australia 2020
We care about your experience, please let us know if you have any suggestions to improve our site.